Cap Insulin Costs and Speed Competition

Summary#

This bill aims to lower what people pay for insulin and to speed up competition from generics and biosimilars. It requires many health plans to cover certain insulin products with no deductible and caps cost-sharing. It also requires pharmacy benefit managers (PBMs) to pass rebates for insulin back to plans, makes changes to FDA petition and biosimilar rules to reduce delays, and funds programs for uninsured people who need insulin.

• Cost-sharing cap and no deductible: For plan years starting January 1, 2027, plans must cover at least one product of each insulin type and dosage form chosen by the plan (“selected insulin products”) with no deductible and with per-30-day cost-sharing capped at $35 in 2027. For plan years starting January 1, 2028 and later, cost-sharing must be the lesser of $35 or 25% of the plan’s negotiated price after price concessions.
• No routine prior authorization: Plans may not impose prior authorization or similar management requirements on these selected insulin products except for safety or reasonable quantity limits.
• Rebate pass-through: PBMs and similar entities must remit 100% of rebates, fees, discounts, and other remuneration related to insulin back to the group health plan, disclose them, and allow audits.
• FDA and competition changes: The bill tightens rules on citizen petitions that can delay generic or biosimilar approvals, allows the FDA to refer delay petitions to the FTC, and creates a process to expedite biosimilar review when competition is limited.
• Uninsured programs and supports: It creates a 5‑year pilot giving grants to 10 states to provide low-cost insulin to uninsured people (defines “affordable” as $35 per 1‑month supply) and authorizes $100 million for that pilot for FY2027. It also funds a national resource center and hotline and directs a GAO study of uninsured insulin users.

What it means for you#

• People with private insurance (group or individual plans):

  • If your plan selects a covered insulin product, you should not have to meet a deductible for that insulin.
  • Your cost per 30‑day supply for that selected insulin will be no more than $35 in 2027. From 2028 it will be no more than $35 or 25% of the plan’s negotiated price (whichever is less).
  • Payments you make for this insulin count toward your plan deductible and out-of-pocket maximum.
  • Your plan generally cannot require prior authorization for the selected insulin, unless for safety or reasonable quantity limits.

• People in catastrophic plans or retirees and small group plans:

  • The bill extends these protections to certain catastrophic, retiree, and specified small group plans as written in the bill.

• Uninsured people who need insulin:

  • The bill funds a pilot program in 10 states to help uninsured people get insulin at a cost of up to $35 per month.
  • It also plans a national resource center and 24/7 hotline to help uninsured people find assistance programs and enroll in them.

• Employers, plan sponsors, and plan administrators:

  • Plans must add and cover at least one insulin product per type/dosage form chosen by the plan under the new cost rules.
  • Plan sponsors will receive full disclosure of insulin-related rebates and have the right to audit those payments.

• Pharmacies and PBMs:

  • PBMs and entities providing pharmacy management services must remit all insulin-related rebates and fees to plans within 90 days, fully disclose them, and be available for audits.
  • PBMs will lose discretion to retain insulin-related rebate revenue for themselves.

• Drug manufacturers and FDA-regulated applicants:

  • The bill changes the citizen petition process and adds criteria for petitions that may be seen as delaying approvals. It also creates an expedited pathway for biosimilars when competition is judged inadequate.

Expenses#

Estimated public cost: The bill authorizes specific federal funding but provides no overall federal cost estimate for the insurance changes.

• Authorized appropriations:
  • $100,000,000 authorized for the 5‑year pilot program for states (FY2027, to remain available until expended).
  • $2,000,000 per year authorized for the resource center and hotline for each of fiscal years 2027 through 2032 (total authorization of $12,000,000 across those years).
• Other federal costs or savings: No overall fiscal note or estimate for how the insurance coverage and rebate rules would affect federal spending, tax receipts, Medicare/Medicaid costs, or private insurance premiums is provided in the bill text.
• Administrative and compliance costs:
  • Plans, PBMs, and insurers will face administrative work to track, remit, disclose, and audit rebate flows and to change benefit designs.
  • States receiving pilot grants must report on fund use and service numbers; the Secretary must oversee standards and may reaward grants if standards are not met.
• No publicly available information in the bill text on projected impacts to premiums, PBM revenue, manufacturer revenue, or employer costs.

Proponents' View#

• The bill appears intended to make insulin more affordable and predictable for people who use it by capping out-of-pocket costs and removing deductibles for covered insulin products.
• Requiring PBMs to pass through 100% of insulin rebates to plans could increase transparency and ensure plan sponsors see the full value of manufacturer discounts.
• Tightening citizen petition rules and creating an expedited path for biosimilars aims to reduce deliberate delays and speed competitive products to market, which could increase competition and lower prices.
• The pilot grants, resource center, and hotline aim to help uninsured people access insulin at affordable prices and guide them to assistance programs.
• The bill allows federal agencies to implement insurance changes by guidance to speed roll-out (implementation flexibility).

Opponents' View (concerns and trade-offs)#

• One concern is that the bill gives plans discretion in selecting which insulin products are “selected insulin products.” This could mean some specific brand or product a patient uses might not be covered under the low cost-sharing rules if the plan does not select it.
• It is unclear how the required cost-sharing cap tied to “25 percent of the negotiated price net of all price concessions” will be calculated in practice. Plans and PBMs may have differing methods for reporting negotiated prices and concessions.
• Requiring pass-through of 100% of insulin-related rebates to plans could reduce revenue streams for PBMs. This may lead to higher administrative fees charged to plans or other shifts in how plans design benefits; the bill does not spell out how such changes would be measured or offset.
• The bill does not include a fiscal estimate for broader effects on premiums, employer costs, or federal health program spending. This makes it hard to judge overall budget impacts.
• The citizen petition and expedited biosimilar provisions leave some implementation details to the Secretary (including guidance and criteria). It is unclear how these changes will affect legal challenges, FDA workload, or whether they will fully prevent delay tactics.
• The Paperwork Reduction Act is waived for the title that changes plan rules. That could speed implementation but reduces a standard federal review that often assesses reporting burdens.

What is unclear: The bill does not specify exactly which insulin products every plan must choose, how negotiated price net concessions will be defined and verified across different plans, or the net effect on premiums and plan spending.